Anti-cancer attacks difficult cancer

New findings of molecular research describes a tool that shows that the great therapeutic promise of human acute myeloid leukemia (AML), a known cancer-resistant blood. The study, published by Cell Press in the July 2nd edition of the journal Cell Stem Cell, explains exciting preclinical studies, where a new therapeutic approach human selectively attacks cancer cells in laboratory and animal models of leukemia.

AML is a cancer of white blood cells, the very poor prognosis and is not well to traditional chemotherapy. "The molecular and cellular basis of the dark image is unclear, the author proposes to study Senior Associate Professor Richard Lock, Children's Cancer Institute Australia and the University of New South Wales." But , previous research has suggested that leukemia stem cells (LSC) may at heart after treatment and recidivism chemoresistance. "LSC are cells, introduction and AML are essential to the long-term growth.

Junior Lock professor and his colleagues have used the fact that the CD123 molecule is very high on LSC but not on normal blood cells. CD123 is a part of the interleukin-3 receptor, a protein that interacts with a growth rate (a "cytokines), have an impact on survival and cell proliferation. Researchers who have a therapeutic antibody recognized and bound to CD123 in the hope that these antibodies with selective AML LSC survival.

In the AML-LSC human patients have been transplanted in mice with the antibody, called 7G3, cytokine-signaling in tumor cells was blocked. For more details, 7G3 affects migration of AML LSC to bone marrow and activates the innate immune system of the host mouse to destroy AML LSC. Overall, treatment with 7G3 mouse survival significantly improved compared to control groups. The researchers go on a report that anti-CD123 targeting is currently in Phase 1 clinical trials advanced AML and that there was no sign of toxicity in the treatment.

These results are in great promise for the future of cancer therapy. "The recent characterization of defined populations of cancer stem cells in a number of human cancers, and their relative resistance to conventional chemotherapy and radiotherapy, supports the applicability of our broad approach and the reasons for the progression of LAM - LSC treatments clinical evaluation pre-clinical, "concludes Professor Lock